ClinicalTrials.gg
Not yet recruitingNCT06211751Updated Jan 18, 2024

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

A Phase 1 interventional study of TQB3909 tablets and TQB3702 tablets in Hematologic Malignancy, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
208
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 148 studies in Hematologic Neoplasms with a site in China — 75 open to participants now, 83 under way, 8 of them phase 3. Hematologic Neoplasms · China.

Planned enrollment
16th of 123
208 · median 56
Started
2024
with 15 others
Phase 1
57 of 148
30 open now
Primary completion
2025-12
later than 22 of 82 live
Registered
94th of 148
by date
Lead sponsor
4 of 148
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 148 studies in Hematologic Neoplasms with a site in China, this one is the 16th largest by planned enrollment of the 123 interventional ones that give a count, is one of 16 that started in 2024, is one of 57 in phase 1, reaches primary completion later than 22 of the 82 other live ones, and was the 94th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

75 of the 148 studies in Hematologic Neoplasms with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Hematologic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is an open, multi-cohort clinical study. The first phase is a dose escalation study and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety and preliminary efficacy of TQB3909 tablets combined with TQB3702 tablets in hematologic malignancy subjects.

03

Conditions studied

  • Hematologic Malignancy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily joined the study, signed form, and with good compliance.
  • ≥ 18 years old, ≤75 years old (when signing informed consent form); (ECOG) physical status: 0-2; at least 3 months expected survival period.
  • Subject population:

    1. Dose escalation stage: non-Hodgkin's B-cell lymphoma;
    2. Dose expansion stage: non-Hodgkin's lymphoma, etc.
  • At least 1 lesion / for efficacy evaluation.
  • The function of main organs is normal.
  • Female patients of childbearing age should agree to use measures during the study period and for at least 6 months after the completion of the study; a negative serum pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects; male patients should agree to use contraception during the study period and for at least 6 months after the completion of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients has occured or is currently having other malignant tumors within 5 years. The following two conditions can be included: other malignant tumors treated with a single operation to achieved 5 consecutive years of disease free survival (DFS). Cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basal membrane)] and papillary thyroid carcinoma.
  • Burkitt lymphoma, lymphoblastic lymphoma/leukemia, etc.
  • For cohort A and cohort B: Richter transformation occured.
  • Subjects with central nervous system (CNS) aggression;
  • Previously received hematopoietic stem cell transplantation;
  • For Cohort B/D/E: Received autologous hematopoietic stem cell transplantation within 3 months before the first dose;
  • Multiple factors that affect the absorption of oral medications (e.g., inability to swallow, chronic diarrhea, and intestinal obstruction);
  • Unrelieved toxicity of ≥ grade 1 due to any previous treatment, excluding alopecia and fatigue;
  • Major surgical treatment, open , and significant traumatic injury received within 28 days before the start of study treatment.
  • Having active or uncontrolled primary hemocytopenia, including autoimmune hemolytic anemia (AIHA), primary immune thrombocytopenia (ITP), etc.
  • Patients with evidence or history of bleeding constitution; Or any bleeding event (such as gastrointestinal bleeding) greater than or equal to CTCAE level 3 within 4 weeks before the first dose;
  • Subjects who had an arteriovenous thrombosis event within 6 months.
  • Subjects who had a history of psychotropic substance abuse and are unable to abstain or have mental disorders;
  • Subjects with any severe and/or uncontrolled disease.
  • Within one weeks before the first dose, the subjects had received proprietary Chinese medicines with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions;
  • Study treatment related: subjects received live or mRNA vaccines within 4 weeks before the first treatment or were scheduled to receive live or mRNA vaccines during the study;
  • Participated in clinical trials of other antitumor drugs within 4 weeks before the first dose;
  • According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered unsuitable for enrollment for other reasons
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    TQB3909 tablets+ TQB3702 tablets

    TQB3909 tablets combined with TQB3702 tablets, administered orally, 28 days as a treatment cycle.

    Drug: TQB3909 tablets · Drug: TQB3702 tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Dose limited toxicity (DLT)

    DLT will be defined as toxicities that meet pre-defined severity criteria (according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0), and assessed as having a suspected relationship to study drug.

    Time frame: Baseline up to 104 weeks

  2. Adverse events (AE)

    The occurrence of all adverse events (AE).

    Time frame: Baseline up to 104 weeks

  3. Serious adverse events (SAE)

    The occurrence of all serious adverse events (SAE).

    Time frame: Baseline up to 104 weeks

  4. Clinical laboratory abnormalities

    Incidence of participants with abnormal clinical laboratory test results.

    Time frame: Baseline up to 104 weeks

Secondary outcomes

  1. Complete remission rate (CRR)/ Complete remission with incomplete bone marrow recovery rate (CRi)

    The proportion of patients with tumor hat have a complete response or complete remission with incomplete bone marrow recovery after treatment.

    Time frame: Baseline up to 104 weeks

  2. Objective Response Rate (ORR)

    The proportion of patients with tumor size reduction of a predefined amount and for a minimum time period.

    Time frame: Baseline up to 104 weeks

  3. Undetectable measurable residual disease (U-MRD) ratio of peripheral blood and/or bone marrow

    Refers to the undetected residual lesions. Flow cytometry was used to detect less than 1 Chronic Lymphocytic Leukemia (CLL) cell (less than 10-4) in 10,000 white blood cells in peripheral blood and/or bone marrow.

    Time frame: Baseline up to 104 weeks

  4. Duration of complete remission / complete remission with incomplete bone marrow recovery

    The time from the date of first achieving CR or CRi to the date of first definite disease progression or death from any cause (whichever occurs first).

    Time frame: Baseline up to 104 weeks

  5. Duration of Response (DOR)

    For all subjects whose best response was partial response (PR), Complete Response (CR), the time from the date of first achieving PR, CR to the date of first definite disease progression or death from any cause (whichever occurs first).

    Time frame: Baseline up to 104 weeks

  6. Time to complete remission

    The time from beginning the treatment to the first achieving complete remission/ complete remission with incomplete bone marrow recovery.

    Time frame: Baseline up to 104 weeks

  7. Time to remission (TTR)

    Time from the beginning of treatment to the first recording of remission (PR or better remission), only the remission population will be analyzed.

    Time frame: Baseline up to 104 weeks

  8. Progression Free Survival (PFS)

    The time from the first dose to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first

    Time frame: Baseline up to 104 weeks

  9. Overall Survival (OS)

    The time from start of study treatment to date of death due to any cause.

    Time frame: Baseline up to 104 weeks

  10. 2 years' PFS rate

    The proportion of patients with progression free survival in 2 years.

    Time frame: Baseline up to 104 weeks

  11. 2 years' OS rate

    The proportion of patients achieving overall survival in two years.

    Time frame: Baseline up to 104 weeks

  12. Time to reach the maximum plasma concentration (Tmax)

    Time to reach the maximum plasma concentration after dose

    Time frame: Before the first dose of TQB3702 tablet and target dose of TQB3909 tablet. 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after the first target dose of TQB3909 tablet. The 4th /11th day before dosing with target dose of TQB3909 tablet.

  13. Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)

    Cmax is the maximum plasma concentration of TQB3909 and TQB3702

    Time frame: Before the first dose of TQB3702 tablet and target dose of TQB3909 tablet. 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after the first target dose of TQB3909 tablet. The 4th /11th day before dosing with target dose of TQB3909 tablet.

  14. Minimum steady-state plasma drug concentration during a dosage interval (Css-min)

    Cmin is the minimum plasma concentration of TQB3909 and TQB3702.

    Time frame: Before the first dose of TQB3702 tablet and target dose of TQB3909 tablet. 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after the first target dose of TQB3909 tablet. The 4th /11th day before dosing with target dose of TQB3909 tablet.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Dec 2025, 23 months later.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 23 months is below that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Jan 18, 2024
StartEst.
Jan 2024
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
Jan 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06211751
Responsible party
Sponsor
First posted
Jan 18, 2024
Start date
Jan 2024 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jan 18, 2024

Study contacts

Yanyan Liu, Doctor
Contact
yyliu@zzu.edu.cn
+86-13838176375

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bcl-2 Inhibitor TQB3909 · BTK Inhibitor TQB3702

Start the discussion